Sangamo BioSciences | SGMO - Current Liabilities


Sangamo BioSciences reported $47.66M in Current Liabilities for its fiscal quarter ending in June of 2025.





Current Liabilities Change Date
Alaunos Therapeutics USD 595K 218K Mar/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
Amgen USD 25.5B 547M Jun/2026
Bayer EUR 32.27B 1.19B Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.04M 533K Mar/2026
CSL USD 4.61B 207M Dec/2025
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Grifols EUR 2.37B 156.97M Dec/2025
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Merck USD 27.73B 786M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Omeros USD 85.5M 2.28M Jun/2025
Pfizer USD 32.65B 1.7B Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 31.93B 1.92B Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Tectonic Therapeutic USD 12.96M 3.29M Mar/2026
Ultragenyx Pharmaceutical USD 351M 26M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026